Protease-activated receptors (PAR)-1 and -3 drive epithelial-mesenchymal transition of alveolar epithelial cells – potential role in lung fibrosis

Summary

Extravascular activation of the coagulation cascade in the lung is commonly observed in pulmonary fibrosis. Coagulation proteases may exert profibrotic cellular effects via protease-activated receptors (PARs)-1 and -2. Here, we investigated the potential role of two other members of the PAR family, namely PAR-3 and PAR-4, in the pathobiology of lung fibrosis. Elevated expression of PAR-3, but not PAR-4, was detected in the lungs of idiopathic pulmonary fibrosis (IPF) patients and in bleomycin-induced lung fibrosis in mice. Increased PAR-3 expression in fibrotic lungs was mainly attributable to alveolar type II (ATII) cells. Stimulation of primary mouse ATII, MLE15 and A549 cells with thrombin (FIIa) – that may activate PAR-1, PAR-3 and PAR-4 – induced epithelial-mesenchymal transition (EMT), a process that has been suggested to be a possible mechanism underlying the expanded (myo)fibroblast pool in lung fibrosis. EMT was evidenced by morphological alterations, expression changes of epithelial and mesenchymal phenotype markers, and functional changes. Single knockdown of FIIa receptors, PAR-1, PAR-3, or PAR-4, had no major impact on FIIa-induced EMT. Simultaneous depletion of PAR-1 and PAR-3, however, almost completely inhibited this process, whereas only a partial effect on FIIa-mediated EMT was observed when PAR-1 and PAR-4, or PAR-3 and PAR-4 were knocked down. PAR-1 and PAR-3 co-localise within ATII cells with both being predominantely plasma membrane associated. In conclusion, our study indicates that PARs synergise to mediate FIIa-induced EMT and provides first evidence that PAR-3 via its ability to potentiate FIIa-triggered EMT could potentially contribute to the pathogenesis of pulmonary fibrosis.

Keywords

Coagulation proteases - thrombin - protease-activated receptors - pulmonary fibrosis - epithelial-mesenchymal transition

^* Members of the German Center for Lung Research (DZL).

• References

• 1 Panos RJ, Mortenson RL, Niccoli SA. et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396-404.
• 2 Pardo A, Selman M. Molecular mechanisms of pulmonary fibrosis. Front Biosci 2002; 07: d1743-1761.
• 3 Gunther A, Mosavi P, Ruppert C. et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83: 853-860.
• 4 Wygrecka M, Markart P, Ruppert C. et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J 2007; 29: 1105-1114.
• 5 Chambers RC, Dabbagh K, McAnulty RJ. et al. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 1998; 333: 121-127.
• 6 Blanc-Brude OP, Archer F, Leoni P. et al. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res 2005; 304: 16-27.
• 7 Scotton CJ, Krupiczojc MA, Konigshoff M. et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119: 2550-2563.
• 8 Howell DC, Johns RH, Lasky JA. et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166: 1353-1365.
• 9 Mercer PF, Johns RH, Scotton CJ. et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 414-425.
• 10 Wygrecka M, Kwapiszewska G, Jablonska E. et al. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 1703-1714.
• 11 Borensztajn K, Bresser P, van der Loos C. et al. Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis. Am J Pathol 2010; 177: 2753-2764.
• 12 Su X, Matthay MA. Role of protease activated receptor 2 in experimental acute lung injury and lung fibrosis. Anat Rec (Hoboken) 2009; 292: 580-586.
• 13 Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
• 14 Asokananthan N, Graham PT, Fink J. et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002; 168: 3577-3585.
• 15 Ostrowska E, Reiser G. The protease-activated receptor-3 (PAR-3) can signal autonomously to induce interleukin-8 release. Cell Mol Life Sci 2008; 65: 970-981.
• 16 Jesmin S, Gando S, Zaedi S. et al. Differential expression, time course and distribution of four PARs in rats with endotoxin-induced acute lung injury. Inflammation 2007; 30: 14-27.
• 17 Jesmin S, Gando S, Matsuda N. et al. Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost 2004; 92: 966-979.
• 18 Raghu G, Collard HR, Egan JJ. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
• 19 Kage H, Borok Z. EMT and interstitial lung disease: a mysterious relationship. Curr Opin Pulm Med 2012; 18: 517-523.
• 20 Kim KK, Kugler MC, Wolters PJ. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103: 13180-13185.
• 21 Willis BC, Liebler JM, Luby-Phelps K. et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166: 1321-1332.
• 22 Kaufmann R, Schulze B, Krause G. et al. Proteinase-activated receptors (PARs)--the PAR3 Neo-N-terminal peptide TFRGAP interacts with PAR1. Regul Pept 2005; 125: 61-66.
• 23 Kimura M, Tani K, Miyata J. et al. The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases. J Med Invest 2005; 52: 93-100.
• 24 Howell DC, Goldsack NR, Marshall RP. et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 159: 1383-1395.
• 25 Suga M, Iyonaga K, Okamoto T. et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000; 162: 1949-1956.
• 26 Schmidt VA, Nierman WC, Maglott DR. et al. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 1998; 273: 15061-15068.
• 27 D’Andrea MR, Saban MR, Nguyen NB. et al. Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. Am J Pathol 2003; 162: 907-923.
• 28 Jesmin S, Gando S, Zaedi S. et al. Chronological expression of PAR isoforms in acute liver injury and its amelioration by PAR2 blockade in a rat model of sepsis. Thromb Haemost 2006; 96: 830-838.
• 29 Kasai H, Allen JT, Mason RM. et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005; 06: 56.
• 30 Jayachandran A, Konigshoff M, Yu H. et al. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. Thorax 2009; 64: 1053-1061.
• 31 Nakanishi-Matsui M, Zheng YW, Sulciner DJ. et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-613.
• 32 Vidwan P, Pathak A, Sheth S. et al. Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2010; 30: 2587-2596.
• 33 McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA 2007; 104: 5662-5667.
• 34 Ando S, Otani H, Yagi Y. et al. Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2007; 08: 31.
• 35 Borensztajn K, Duitman J, Bruggemann LW. et al. Protease-activated receptor-4 deficiency does not protect against bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2012; 40: 1056-1057.
• 36 O’Brien PJ, Prevost N, Molino M. et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000; 275: 13502-13509.
• 37 Madhusudhan T, Wang H, Straub BK. et al. Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood 2012; 119: 874-883.
• 38 Afonso C, Henrique D. PAR3 acts as a molecular organizer to define the apical domain of chick neuroepithelial cells. J Cell Sci 2006; 119: 4293-4304.